Focus: Longeveron is a public biotechnology company focused on allogeneic mesenchymal stem cell (MSC) therapies targeting age-related diseases including Alzheimer's, frailty, and rare cardiac conditions. The company operates at pre-revenue scale with a highly experimental pipeline in early clinical phases.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Longeveron to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Longeveron
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Longeveron's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells - Finansavisen
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells Finansavisen
If You Invested $1,000 in Longeveron Inc (LGVN) - Stock Titan
If You Invested $1,000 in Longeveron Inc (LGVN) Stock Titan
Longeveron Funding & Clinical Strategy: ELPIS II Results Expected Q3 2026 - News and Statistics - IndexBox
Longeveron Funding & Clinical Strategy: ELPIS II Results Expected Q3 2026 - News and Statistics IndexBox
Stem cell bet on rare heart defect: Longeveron eyes 2026 trial results - Stock Titan
Stem cell bet on rare heart defect: Longeveron eyes 2026 trial results Stock Titan
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - Bitget
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update Bitget
Longeveron Appoints Stephen Willard as CEO - citybiz
Longeveron Appoints Stephen Willard as CEO citybiz
Showing 6 of 9 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo